- Home
- CGEN
CGEN
Compugen Ltd.
as of 02-23-2026 3:47pm EST
$1.73
+$0.02
+0.88%
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
| Founded: | 1993 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 148.7M | IPO Year: | 2001 |
| Target Price: | $4.00 | AVG Volume (30 days): | 203.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $1.13 - $2.38 | Next Earning Date: | 01-01-0001 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | -75.23% | Revenue Growth (next year): | 164.92% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
Latest Compugen Ltd. News
CGEN Breaking Stock News: Dive into CGEN Ticker-Specific Updates for Smart Investing
PR Newswire
Compugen to Participate in Upcoming Investor Conferences
📊
AI Sentiment
Positive
7/10
PR Newswire
Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026
âž–
AI Sentiment
Neutral
5/10
Compare CGEN vs Leading Stocks
See how CGEN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CGEN Compugen Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.